We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Therapeutic indications
Surgery: Atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and
bronchial secretions and to diminish the risk of vagal inhibition of the heart. The use of atropine as an antisialagogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. Atropine may be administered concurrently with anticholinesterase agents (e.g.neostigmine, physostigmine) to block the adverse muscarinic effects when they are used after surgery to terminate curarisation.
Cardiopulmonary Resuscitation: It may be used in the management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability.
Anticholinesterase Poisoning: It is also used concomitantly with a cholinesterase reactivator (e.g.
pralidoxime) to reverse muscarinic effects associated with toxic exposure to anticholinesterase
compounds (e.g. organophosphate pesticides).
Atropine may be used in conjunction with morphine or other agents for the relief of biliary or renal
colic.
Dose and method of administration
Atropine Sulfate Injection may be administered by subcutaneous (SC), intramuscular (IM) or direct
intravenous (IV) injection. Atropine Sulfate Injection contains no antimicrobial agent. It should be used only once and any residue discarded. Atropine Sulfate Injection should not be added to any IV infusion solution.
Surgery
Adults:
300-600 mcg of Atropine Sulfate Injection IM or SC, approximately 1 hour before anaesthesia, usually in conjunction with a narcotic. Alternatively, 300-600 mcg Atropine Sulfate Injection may be given IV immediately prior to induction of anaesthesia. To reverse the effects of non-depolarising muscle relaxants, 600 mcg - 1.2 mg Atropine Sulfate Injection may be given to adults as a slow IV injection in conjunction with the anticholinesterase agent(e.g. neostigmine methylsulphate) of choice.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
